In this episode of 'Talking About Glaucoma,' host Rob Schertzer, a Vancouver-based glaucoma specialist, chats with guest Gavin Docherty about the evolving understanding of preservative-free therapies in glaucoma management. They discuss the historical rationale for including preservatives in eye drops and the recent studies showing that preservative-free options are equally effective while reducing side effects such as hyperemia, burning, and irritation. The conversation covers the benefits of preservative-free drops in terms of improving patient compliance and minimizing ocular surface damage, which could potentially lead to fewer surgeries and better outcomes. They also share clinical experiences and highlight the barriers to transitioning patients to preservative-free medications, including issues related to cost, accessibility, and environmental waste. The episode concludes with an emphasis on the importance of collaboration among eye care providers to enhance patient care.
All content for Talking About Glaucoma (mp3) is the property of Robert M Schertzer, MD, MEd, FRCSC and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of 'Talking About Glaucoma,' host Rob Schertzer, a Vancouver-based glaucoma specialist, chats with guest Gavin Docherty about the evolving understanding of preservative-free therapies in glaucoma management. They discuss the historical rationale for including preservatives in eye drops and the recent studies showing that preservative-free options are equally effective while reducing side effects such as hyperemia, burning, and irritation. The conversation covers the benefits of preservative-free drops in terms of improving patient compliance and minimizing ocular surface damage, which could potentially lead to fewer surgeries and better outcomes. They also share clinical experiences and highlight the barriers to transitioning patients to preservative-free medications, including issues related to cost, accessibility, and environmental waste. The episode concludes with an emphasis on the importance of collaboration among eye care providers to enhance patient care.
Ep 31 Talking About Glaucoma - 6Jun2019 LEWIS Rick Rho Kinase Inhibitors: a new class of drugs (mp3)
Talking About Glaucoma (mp3)
12 minutes 13 seconds
6 years ago
Ep 31 Talking About Glaucoma - 6Jun2019 LEWIS Rick Rho Kinase Inhibitors: a new class of drugs (mp3)
The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of trying, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals.
Talking About Glaucoma (mp3)
In this episode of 'Talking About Glaucoma,' host Rob Schertzer, a Vancouver-based glaucoma specialist, chats with guest Gavin Docherty about the evolving understanding of preservative-free therapies in glaucoma management. They discuss the historical rationale for including preservatives in eye drops and the recent studies showing that preservative-free options are equally effective while reducing side effects such as hyperemia, burning, and irritation. The conversation covers the benefits of preservative-free drops in terms of improving patient compliance and minimizing ocular surface damage, which could potentially lead to fewer surgeries and better outcomes. They also share clinical experiences and highlight the barriers to transitioning patients to preservative-free medications, including issues related to cost, accessibility, and environmental waste. The episode concludes with an emphasis on the importance of collaboration among eye care providers to enhance patient care.
